Plasmodium vivax Duffy binding protein (PvDBP) binds the Duffy blood group antigen as the obligate receptor for erythrocyte invasion. We have tested in mice the immunogenicity of recombinant P. vivax region II (PvRII), the receptor-binding domain of PvDBP, formulated with five adjuvants, namely, Montanide ISA720, AS02A, alum, QS21 and MF59. All the formulations elicited high titer antibodies, with Montanide ISA720 and AS02A yielding the highest titers followed by MF59, QS21 and alum. Sera raised against PvRII formulated with AS02A and Montanide ISA720 followed by alum were most effective at blocking PvRII binding to erythrocytes in a functional assay. Analysis of cellular immune responses indicated that all adjuvant groups induced significant interferon-gamma, with alum being the highest interferon-gamma inducer. These results suggest that recombinant PvRII formulated with human compatible adjuvants is immunogenic in small animal models and that Montanide ISA720, AS02A and alum perform better than MF59 and QS21 in terms of their ability to elicit high titer binding inhibitory antibodies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2004.03.030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- The study investigated the use of engineered outer membrane vesicles (OMVs) from ClearColi™ as both an adjuvant and a carrier for a novel vaccine targeting HIV-1 antigens Nef and Nef-Tat.
- Researchers isolated recombinant OMVs (rOMVs) containing specific fusion proteins and confirmed their presence through western blotting.
- Results showed that rOMVs induced stronger immune responses, including higher levels of IgG2a and IFN-γ, compared to traditional adjuvants, indicating their potential as effective vaccine carriers against HIV-1.
Determination of the safety and efficacy of recombinant Chlamydia muridarum MOMP vaccines, formulated with CpG-1826 and 70%, 50%, 30% or 10% concentrations of Montanide ISA-720 VG, to elicit protective immune responses against a C. muridarum respiratory challenge.
Res Sq
December 2023
Lawrence Livermore National Laboratory.
To determine the safety and protective efficacy of a MOMP vaccine, formulated with CpG-1826 and four different concentrations of Montanide ISA 720 VG (70%, 50%, 30% and 10%), BALB/c mice were immunized twice intramuscularly. Local reactogenicity was significant for vaccines formulated with 70% and 50% Montanide but not in mice receiving 30% and 10% Montanide. Robust humoral and cell mediated memory immune responses were elicited by the 70%, 50% and 30% Montanide formulations.
View Article and Find Full Text PDFComparison of Adjuvant Effects of Montanide ISA-720 and Heat Shock Protein 27 in Increasing Immunostimulatory Properties of HIV-1 Nef-Vif Fusion Protein Construct.
Protein Pept Lett
July 2023
Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
Article Synopsis
- Effective T-cell immunity plays a crucial role in HIV-1 vaccination, specifically targeting proteins like Nef and Vif that aid the virus in evading the immune system.
- The study aims to compare the immunostimulatory effects of Montanide ISA-720 and heat shock protein 27 (Hsp27) on an HIV-1 Nef-Vif fusion protein as a potential vaccine.
- Results showed that Hsp27 significantly enhanced immune responses, generating higher levels of antibodies and signaling molecules compared to the commercial adjuvant Montanide ISA-720, suggesting its effectiveness for future vaccine development against HIV-1.
Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4 and CD8 T cells for immunotherapy of cancer.
J Immunother Cancer
September 2022
ISA Pharmaceuticals, Leiden, The Netherlands
Water-in-oil emulsion incomplete Freund's adjuvant (IFA) has been used as an adjuvant in preventive and therapeutic vaccines since its development. New generation, highly purified modulations of the adjuvant, Montanide incomplete seppic adjuvant (ISA)-51 and Montanide ISA-720, were developed to reduce toxicity. Montanide adjuvants are generally considered to be safe, with adverse events largely consisting of antigen and adjuvant dose-dependent injection site reactions (ISRs).
View Article and Find Full Text PDFMontanide ISA-720 and Naloxone in HBsAg Vaccine Formulation: Cytokine Profiling and Monitoring of Long-Lasting Humoral Immune Responses.
Biomed Environ Sci
September 2022
Advanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center, Motamed Cancer Institute, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran;Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran;Department of Immunology, Pasteur Institute of Iran, Tehran, Iran;Immunotherapy Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Objective: This study aimed to investigate the effects of Montanide ISA-720 and Naloxone (NLX) in Hepatitis B surface antigen (HBsAg) vaccine formulation on cytokine and long-lasting antibody responses.
Methods: First, the HBsAg was formulated in Montanide ISA-720 adjuvant and Naloxone at 5 and 10 mg/kg. The experimental mice were immunized three times at a 2-week interval, and then IL-4, IL-2, TNF-α, and IFN-γ cytokines; long-lasting IgG antibody responses 220 days after the last shot; and IgG1/IgG2a isotypes were assessed by ELISA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!